Everolimus after surgery can improve outcomes in those with high-risk kidney cancer
June 03, 2022
At the annual American Society of Clinical Oncology conference, Christopher Ryan, M.D., presents results of a study on the drug everolimus. The findings suggest the drug can improve outcomes in those with high-risk kidney cancer.